If you have been reading about drug affinity complex and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
=== Antagonists and inverse agonists === Non-selective Agouti-related peptide Agouti signalling peptide MC2-selective Atumelnant (CRN04894) MC4-selective HS-014 HS-024 MCL-0042 MCL-0129 MPB-10 SHU-9119 (agonist at MC1 and MC5, antagonist at MC3 and MC4)
He continued to perform in London, and in 1914 took part in the inaugural theatre performance held within the new ocean liner, RMS Aquitania, before its first sailing from Liverpool. Gammon died in Maida Vale, London, in June 1915, aged 48.
== Related preservation methods == Other methods have been in place for thousands of years to halt the decomposition of the body. Mummification used by the ancient Egyptians is a widely known method which involves the removal of body fluid and wrapping the body in linens. Prior to mummification, Egyptians would lay the body in a shallow pit in the desert and allow the sun to dehydrate the body. Formalin, an important solution to body preservation, was introduced in 1896 to help with body preservation. Soon to follow formalin, color-preserving embalming solutions were developed to preserve lifelike color and flexibility to aid in the study of the body. Paraffin impregnation was introduced in 1925, and the embedding of organs in plastic was developed in the 1960s. Body preservation methods current to the 21st century are cryopreservation, which involves the cooling of the body to very low temperatures to preserve the body tissues, plastination, and embalming. Other methods used in modern times include the Silicone S 10 Standard Procedure, the Cor-Tech Room temperature procedure, the Epoxy E 12 procedure, and the Polyester P 35 (P 40) procedure. The Silicone S 10 is the procedure most often used in plastination and creates opaque, natural-looking specimen., Dow Corning Corporation's Cor-Tech Room Temperature Procedure is designed to allow plastination of specimen at room temperature to various degrees of flexibility using three combinations of polymer, crosslinker, and catalyst.
== Taxonomy == The first scientific description of Vanilla planifolia was published by Henry Charles Andrews in the eighth volume of his The Botanist's Repository. In his description he credits Charles Plumier with publishing a description of it in 1703 as the third species of the genus Vanilla. Andrews created the drawing in his book from a specimen that bloomed in a hothouse belonging to Charles Greville.
Sources: en.wikipedia.org
Treatments used in children are primarily lifestyle interventions and behavioral techniques, although efforts to increase activity in children have had little success. In the United States, medications are not FDA approved for use in this age group. Brief weight management interventions in primary care (e.g. delivered by a physician or nurse practitioner) have only a marginal positive effect in reducing childhood overweight or obesity. Multi-component behaviour change interventions that include changes to dietary and physical activity may reduce BMI in the short term in children aged 6 to 11 years, although the benefits are small and quality of evidence is low.
=== Lebanon === The Parliament of Lebanon is the Lebanese national legislature. It is elected to a four-year term by universal adult suffrage in multi-member constituencies, apportioned among Lebanon's diverse Christian and Muslim denominations. Its major functions are to elect the president of the republic, to approve the government (although appointed by the president, the prime minister, along with the Cabinet, must retain the confidence of a majority in the Parliament), and to approve laws and expenditure. The name of a deputy in Arabic is Naeb (نائب). The plural of Naeb is Nuwab (نواب).
Deployment of such agents began to accelerate in late 2023 after OpenAI's "function-calling" API was made available, and especially after Anthropic's late 2024 introduction of Model Context Protocol (MCP), a standardised way for LLM agents to gain contextual awareness, and to act on the world by calling various external tools. The term "agentic" only began to be used with any frequency in 2024, popularised in part by researcher Andrew Ng.
== Tissue distribution == LRRC15 displays a highly restricted expression pattern, but is expressed in areas that make up innate immune barriers such as the placenta, skin, activated fibroblasts in wounds, and lymphoid tissues such as the spleen.
Ultrasonography, CT scans, and MRI are used to identify any abnormality in the pituitary or adrenal gland. This helps diagnose if the patient has pituitary-dependent Cushing's or adrenal-dependent Cushing's. Cushing's may cause a breakdown of dermal proteins, causing shiny and thin skin, this can lead to secondary infection and is pathognomonic of Cushing's.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.